Edition:
United Kingdom

Marinus Pharmaceuticals Inc (MRNS.OQ)

MRNS.OQ on NASDAQ Stock Exchange Global Market

3.62USD
8:59pm GMT
Change (% chg)

$-0.09 (-2.43%)
Prev Close
$3.71
Open
$3.60
Day's High
$3.83
Day's Low
$3.59
Volume
390,580
Avg. Vol
229,050
52-wk High
$10.54
52-wk Low
$3.31

Latest Key Developments (Source: Significant Developments)

Marinus Pharmaceuticals Says Entered Into Underwriting Agreement To Offer 12 Mln Shares
10:17pm GMT 

Dec 14 (Reuters) - Marinus Pharmaceuticals Inc ::MARINUS PHARMACEUTICALS INC - ENTERED INTO AN UNDERWRITING AGREEMENT TO OFFER 12 MILLION SHARES AT $3.75PER SHARE - SEC FILING.MARINUS PHARMACEUTICALS INC - OFFERING SIZE IS EXPECTED TO BE $45.0 MILLION.  Full Article

Marinus Pharmaceuticals Prices Public Offering Of 12 Mln Shares At $3.75/Shr
Thursday, 13 Dec 2018 

Dec 12 (Reuters) - Marinus Pharmaceuticals Inc ::MARINUS PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 12.0 MILLION COMMON SHARES PRICED AT $3.75PER SHARE.  Full Article

Marinus Pharmaceuticals Announces Public Offering Of Common Stock
Tuesday, 11 Dec 2018 

Dec 11 (Reuters) - Marinus Pharmaceuticals Inc ::MARINUS PHARMACEUTICALS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 12.0 MILLION COMMON SHARES.MARINUS PHARMACEUTICALS - TO USE PROCEEDS TO ADVANCE PRECLINICAL AND CLINICAL DEVELOPMENT OF GANAXOLONE, INCLUDING CLINICAL TRIAL EXPENSES.  Full Article

Marinus Pharmaceuticals phase 2 clinical trial data show long-term effectiveness of Ganaxolone in reducing seizure frequency in CDKl5 deficiency disorder patients
Tuesday, 4 Dec 2018 

Dec 4 (Reuters) - Marinus Pharmaceuticals Inc ::MARINUS PHARMACEUTICALS PHASE 2 CLINICAL TRIAL DATA SHOW LONG-TERM EFFECTIVENESS OF GANAXOLONE IN REDUCING SEIZURE FREQUENCY IN CDKL5 DEFICIENCY DISORDER PATIENTS.MARINUS PHARMACEUTICALS INC - PREDICTIVE BIOMARKER ALSO IDENTIFIED IN PCDH19-RELATED PEDIATRIC EPILEPSY.MARINUS PHARMACEUTICALS INC - AVERAGE SEIZURE FREQUENCY FOR PATIENTS HAS CONTINUED TO IMPROVE, NOW TO A 66 PERCENT REDUCTION..MARINUS PHARMACEUTICALS INC - TWO PATIENTS NOTED MILD INCREASES IN SEIZURE FREQUENCY AT 12 OR 18-MONTH MARKS RELATIVE TO SIX MONTHS.  Full Article

Marinus Pharma Announces Q3 2018 Financial Results
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Marinus Pharmaceuticals Inc ::MARINUS PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND THIRD QUARTER 2018 FINANCIAL RESULTS.MARINUS PHARMACEUTICALS INC QUARTERLY NET LOSS PER SHARE $0.27.MARINUS PHARMACEUTICALS INC - AT SEPTEMBER 30, 2018, COMPANY HAD CASH, CASH EQUIVALENTS AND INVESTMENTS OF $39.6 MILLION.MARINUS PHARMACEUTICALS INC - BELIEVES THAT CASH, CASH EQUIVALENTS & INVESTMENTS, AS OF SEPT 30, 2018, ARE ADEQUATE TO FUND OPERATIONS INTO 2020.  Full Article

Marinus Pharmaceuticals Reports Quarterly Loss Per Share $0.15
Wednesday, 2 May 2018 

May 2 (Reuters) - Marinus Pharmaceuticals Inc ::MARINUS PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND FIRST QUARTER 2018 FINANCIAL RESULTS.MARINUS PHARMACEUTICALS INC QUARTERLY LOSS PER SHARE $0.15.MARINUS PHARMACEUTICALS INC - AT MARCH 31, 2018, HAD CASH, CASH EQUIVALENTS AND INVESTMENTS OF $52.0 MILLION, COMPARED TO $58.4 MILLION AT DECEMBER 31, 2017.MARINUS PHARMACEUTICALS -BELIEVES THAT ITS CASH, CASH EQUIVALENTS AND INVESTMENTS, AS OF MARCH 31, 2018, ARE ADEQUATE TO FUND ITS OPERATIONS INTO 2020.  Full Article

Marinus Pharmaceuticals files for mixed shelf of up to $200 mln
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Marinus Pharmaceuticals Inc :Marinus Pharmaceuticals Inc - files for a mixed shelf of up to $200 million - SEC filing‍​.  Full Article

Marinus Pharmaceuticals qtrly loss per share $0.15‍​
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Marinus Pharmaceuticals Inc :Marinus Pharmaceuticals provides business update and reports third quarter 2017 financial results.Marinus Pharmaceuticals Inc - ‍"believes" cash, cash equivalents and investments as of Sept 30, 2017 are adequate to fund operations into 2020​.Marinus Pharmaceuticals Inc qtrly loss per share $0.15‍​.Marinus-Initiating Phase 2 feasibility study with ganaxolone iv in patients with refractory status epilepticus, data expected in 2018‍​.  Full Article